Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
25 Years of Innovation and Excellence: Alma Celebrates Silver Anniversary at the Seventh Alma Academy Event in Thailand 2024-09-27 17:00
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting 2024-09-27 15:41
Datasea Announces Fiscal Year 2024 Financial Results with Revenue 6.6x that of 2023 Primarily due to Growth of its 5G AI Business 2024-09-26 21:45
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria 2024-09-26 15:10
Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management 2024-09-26 02:00
The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA 2024-09-25 21:18
Bloomage's Pioneering Pilot-Scale Testing Platform Now Fully Operational, Ushering in New Era of Open Innovation 2024-09-25 21:00
Flat Medical Strengthens Market Leadership with Acquisition of InjeQ Assets, Including FDA-Designated Breakthrough Device IQ-Tip® 2024-09-25 20:00
Samsung Biologics launches development platforms for enhanced therapeutic efficacy 2024-09-25 19:00
Bestqool Pro Series Iteration: Upgraded Design for Enhanced User Experience 2024-09-24 21:00
Noul Demonstrates 'Expert-Level' AI Diagnostic Performance in Europe… Results from Spain's Carlos III Health Institute 2024-09-24 21:00
LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners 2024-09-24 21:00
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP 2024-09-24 21:00
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Generation Immunotherapeutics Discovery 2024-09-24 20:00
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024 2024-09-23 17:40
WuXi Biologics Included in Hang Seng ESG 50 Index 2024-09-23 17:30
Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease Treatments 2024-09-23 15:06
Gymera Reveal A Breakthrough in Smart Home Fitness and Elderly Wellness Solution at Hong Kong Global Sources Consumer Electronics Show 2024 2024-09-21 18:32
Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results 2024-09-21 05:30
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting 2024-09-20 20:30
1 9 10 11 12 13 812